Table 3.

Clinical End Points and Echocardiographic Data After the Procedure in the Propensity Score–Matched Analysis for Nonobese and Morbidly Obese Cohort

Clinical End Points	BMI 18.5–29.9 (n=770)	BMI >35 (n=770)	P Value
In‐hospital mortality	26 (3.4)	28 (3.6)	0.782
In‐hospital or 30‐d mortality	28 (3.6)	35 (4.6)	0.368
Vascular complications
Major	33 (4.3)	51 (6.6)	0.043
Minor	80 (14.1)	61 (9.3)	0.009
Vascular complications femoral access only
Major	32 (4.7)	48 (7.2)	0.052
Minor	79 (16.1)	58 (10)	0.003
Major vascular complications femoral access only by closure type
Percutaneous closure device	22 (4.0)	39 (6.7)	0.046
Surgical cutdown technique	8 (9.3)	9 (15.0)	0.291
Bleeding
Life‐threatening bleeding	22 (2.9)	19 (2.5)	0.659
Major bleeding	37 (4.8)	44 (5.7)	0.421
Life‐threatening and major	59 (7.7)	63 (8.2)	0.706
Minor bleeding	66 (8.6)	55 (7.3)	0.353
AKI
Stage I	85 (13.7)	101 (14.8)	0.548
Stage II and III	24 (3.9)	25 (3.7)	0.859
Any stage	109 (17.5)	126 (18.5)	0.646
Coronary occlusion	5 (0.7)	4 (0.5)	0.738*
Periprocedural Stroke	11 (1.4)	12 (1.6)	0.831
Hospital‐acquired pneumonia	11 (1.57)	10 (1.33)	0.690
New permanent pacemaker implantation	91 (13)	108 (15.6)	0.158
Length of hospital stay, d	6 [5–9]	5 [3–8]	<0.001
Post‐TAVR echocardiogram parameters within 30‐d after TAVR
Moderate‐severe post‐TAVR AR	38 (5.0)	18 (2.5)	0.009
Postprocedural mean aortic valve gradient (mm Hg)	8 [6–11]	10 [7–14]	<0.001
Severe patient‐prosthesis mismatch	7 (1.1)	23 (3.5)	0.004
Device success	678 (88.1)	650 (84.4)	0.038
Echocardiogram parameters at 1‐y after TAVR
1 y mean aortic valve gradient (mm Hg)	8 [6–11]	10 [7–14]	<0.001

Values are expressed as n (%) or median [IQR]. AKI indicates acute kidney injury; AR, aortic regurgitation; BMI, body mass index; and TAVR, transcatheter aortic valve replacement.

^*Fisher’s exact test used.